Development of an inactivated vaccine candidate for SARS-CoV-2
- PMID: 32376603
- PMCID: PMC7202686
- DOI: 10.1126/science.abc1932
Development of an inactivated vaccine candidate for SARS-CoV-2
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.
Copyright © 2020, American Association for the Advancement of Science.
Figures
Comment in
-
Impaired interferon signature in severe COVID-19.Nat Rev Immunol. 2020 Jun;20(6):353. doi: 10.1038/s41577-020-0335-0. Nat Rev Immunol. 2020. PMID: 32355328 Free PMC article. No abstract available.
-
SARS-CoV-2-reactive T cells in patients and healthy donors.Nat Rev Immunol. 2020 Jun;20(6):353. doi: 10.1038/s41577-020-0333-2. Nat Rev Immunol. 2020. PMID: 32355329 Free PMC article. No abstract available.
-
Inactivated vaccine for SARS-CoV-2.Nat Rev Immunol. 2020 Jun;20(6):353. doi: 10.1038/s41577-020-0334-1. Nat Rev Immunol. 2020. PMID: 32355330 Free PMC article. No abstract available.
-
Coronavirus vaccine trials have delivered their first results - but their promise is still unclear.Nature. 2020 May;581(7809):363-364. doi: 10.1038/d41586-020-01092-3. Nature. 2020. PMID: 32433634 No abstract available.
Similar articles
-
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.Cell. 2020 Aug 6;182(3):713-721.e9. doi: 10.1016/j.cell.2020.06.008. Epub 2020 Jun 6. Cell. 2020. PMID: 32778225 Free PMC article.
-
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.Science. 2020 Aug 14;369(6505):806-811. doi: 10.1126/science.abc6284. Epub 2020 May 20. Science. 2020. PMID: 32434945 Free PMC article.
-
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.J Virol. 2024 May 14;98(5):e0176223. doi: 10.1128/jvi.01762-23. Epub 2024 Apr 2. J Virol. 2024. PMID: 38563762
-
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.Int Immunopharmacol. 2020 Sep;86:106717. doi: 10.1016/j.intimp.2020.106717. Epub 2020 Jun 18. Int Immunopharmacol. 2020. PMID: 32585611 Free PMC article. Review.
-
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020. Front Immunol. 2020. PMID: 32973779 Free PMC article. Review.
Cited by
-
The comparison of pathogenicity among SARS-CoV-2 variants in domestic cats.Sci Rep. 2024 Sep 18;14(1):21815. doi: 10.1038/s41598-024-71791-8. Sci Rep. 2024. PMID: 39294189 Free PMC article.
-
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal Transduct Target Ther. 2024 Sep 11;9(1):223. doi: 10.1038/s41392-024-01917-x. Signal Transduct Target Ther. 2024. PMID: 39256346 Free PMC article. Review.
-
Vaccines for Respiratory Viruses-COVID and Beyond.Vaccines (Basel). 2024 Aug 22;12(8):936. doi: 10.3390/vaccines12080936. Vaccines (Basel). 2024. PMID: 39204059 Free PMC article. Review.
-
Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac.Vaccines (Basel). 2024 Aug 15;12(8):919. doi: 10.3390/vaccines12080919. Vaccines (Basel). 2024. PMID: 39204043 Free PMC article.
-
Exploring the associations between gut microbiota composition and SARS-CoV-2 inactivated vaccine response in mice with type 2 diabetes mellitus.mSphere. 2024 Sep 25;9(9):e0038024. doi: 10.1128/msphere.00380-24. Epub 2024 Aug 27. mSphere. 2024. PMID: 39189780 Free PMC article.
References
-
- Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P., Meng J., Zhu Z., Zhang Z., Wang J., Sheng J., Quan L., Xia Z., Tan W., Cheng G., Jiang T., Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27, 325–328 (2020). 10.1016/j.chom.2020.02.001 - DOI - PMC - PubMed
-
- Dhama K., Sharun K., Tiwari R., Dadar M., Malik Y. S., Singh K. P., Chaicumpa W., COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum. Vaccin. Immunother. 10.1080/21645515.2020.1735227 (2020). 10.1080/21645515.2020.1735227 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous